[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601512":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":33,"collaborators":10,"id":35,"slug":10,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":10,"eligibilityCriteria":39,"healthyVolunteers":36,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Zhujiang Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Exposed Group",null,"Participants were planned to receive 2 cycles of intravenous neoad- juvant Tislelizumab (200 mg) every 3 weeks,and Paclitaxel 135-175mg\u002Fm² ,Cisplatin 80-120mg\u002Fm² or Carboplatin 0.3-0.4g\u002Fm² through intravenous infusion each 3-week cycle for 2 cycles.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Xiaozhi LV","CONTACT","+86-020-62782092","lxzsurgeon@126.com",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":10,"country":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Department of Stomatology, Zhujiang Hospital, Southern Medical University","RECRUITING","Guangzhou","Guangdong","China",{"type":26,"coordinates":27},"Point",[28,29],113.25,23.11667,{"lat":29,"lon":28},[32],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":34,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100601512",false,"NCT07111455","Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy","Inclusion Criteria:\n\n1. Oral squamous cell carcinoma (OSCC) diagnosed as locally advanced (T3N0M0, T1-3N1M0, T4aN0-2M0, T1-4aN3M0, or T4bN0-3M0) according to AJCC staging criteria.\n2. Their age ranged from 18 to 80 years;regardless of gender.\n3. Absence of prior head and neck radiation therapy or chemotherapy.\n4. Adequate blood function: white blood cell count (WBC) \\>＝3.5×10\\^9\u002FL, platelet count (PLT) \\>＝75×10\\^9\u002FL：Hemoglobin concentration (HGB) \\>＝90g\u002FL.\n5. Adequate liver function： total bilirubin (TBIL) \\\u003C＝ the upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C＝2.5 times the upper limit of normal.\n6. Adequate renal function：estimated glomerular filtration rate (eGFR) greater than 45 mL\u002Fmin per 1.73 m².\n7. The heart, brain, lung and other vital organs function and general condition can tolerate NACI.\n8. PS score \\\u003C＝2.\n9. Signed informed consent form and voluntarily agreeing to participate in this study.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation (for female participants).\n2. Patients with a history of epilepsy or psychiatric disorders that were not well-controlled.\n3. Patients with severe allergic diathesis or suspected or confirmed alcohol or drug addiction.\n4. Patients who had taken antibiotics within 7 days before enrollment.","ALL","18 Years","80 Years",{"count":44,"type":45},32,"ESTIMATED","OBSERVATIONAL","Investigating the Relationship Between Oral Microbiome Alterations and Tumor Markers in Locally Advanced Oral Squamous Cell Carcinoma (LA-OSCC) After Neoadjuvant Chemoimmunotherapy: Implications for Therapeutic Efficacy, Chemoresistance, and Prognostic Assessment",[49],"Locally Advanced Oral Squamous Cell Carcinoma",[51,52],"Oral Microbiome","Neoadjuvant Chemoimmunotherapy","2025-09-21",{"date":55,"type":56},"2025-09-23","ACTUAL",{"date":58,"type":56},"2025-07-22",{"date":60,"type":45},"2027-07-30",{"name":5,"class":6},1]